Clinical Trial Update: PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating a PCSK9 inhibitor for symptomatic intracranial atherosclerotic stenosis is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Symptomatic Intracranial Atherosclerotic Stenosis

Drugs mentioned

• PCSK9 inhibitor (unspecified)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Symptomatic Intracranial Atherosclerotic Stenosis | Phase 3 | Status: NOT_YET_RECRUITING